Antares Pharma to Present at the Deutsche Bank Securities, Inc. 38th Annual Health Care Conference

  Antares Pharma to Present at the Deutsche Bank Securities, Inc. 38th Annual
  Health Care Conference

Deutsche Bank dbAccess Healthcare Conference 2013

Business Wire

EWING, N.J. -- May 24, 2013

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton,
Ph.D., President and Chief Executive Officer, will present at the Deutsche
Bank Securities, Inc. 38^th Annual Health Care Conference on Thursday May 30,
2013 at 10:40 am Eastern Time.

A live webcast of the presentation will be available via the “Investor
Relations” page of the Antares website, www.antarespharma.com. A replay of the
webcast will also be archived on Antares’ website for 90 days following the
presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products
and topical gel-based medicines. The Company is developing OTREXUP™, a
combination product for the delivery of methotrexate using Medi-Jet™
technology for the treatment of rheumatoid arthritis, poly-articular-course
juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for
testosterone replacement therapy. The Company's technology platforms include
VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™
reusable needle-free injectors marketed as Tjet^® and Zomajet^® by Teva
Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring),
respectively. Antares Pharma has a multi-product deal with Teva that includes
Tev-Tropin^® human growth hormone (hGH), VIBEX™ epinephrine and several other
products. Antares Pharma’s partnership with Ferring includes Zomacton® hGH. In
the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for
overactive bladder that is marketed by Actavis. Elestrin^® (estradiol gel) is
FDA approved for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares
Pharma has two facilities in the U.S. The Parenteral Products Group located in
Minneapolis, Minnesota directs the manufacturing and marketing of the
Company’s reusable needle-free injection devices and related disposables, and
develops its disposable pressure-assisted Medi-Jet and pen injector systems.
The Company’s corporate office and Product Development and Commercial Groups
are located in Ewing, New Jersey.

Contact:

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
 
Press spacebar to pause and continue. Press esc to stop.